Got a good line of products, but the share price seem to go down , could it be due to the weak us dollar.

(Reuters) - Pfizer abandoned its attempt to buy AstraZeneca for nearly 70 billion pounds ($118 billion) on Monday as a deadline approached without a last-minute change of heart by the British drugmaker.

The decision ends a month-long public fight between two of the world's biggest pharmaceutical companies that sparked political concerns on both sides of Atlantic over jobs and corporate tax manoeuvres.

British rules now require an enforced cooling-off period. AstraZeneca could reach out to Pfizer after three months and Pfizer could take another run at its smaller British rival in six months time, whether it is invited back or not.

Astrazenica ceo bought £2m of AZN shares yday-if he is so confident then so am I and as a result jumped as a punt on the bandwagon

Down 5% due to the following:
Deutsche Bank "The US Treasury has announced a package of measures designed to stop US companies taking advantage of inversion deals, including "spin-versions". These appear more far-reaching than anticipated (although they are not retroactive for deals already completed). It is unclear whether the moves threaten completion of to-be-consummated deals, given that other benefits (cost savings, pipeline expansion, strategic elements) may still be sufficient to justify such deals proceeding and that the extent to which the Treasury changes impact the financial benefits cannot be quantified externally (we await the first formal response from one of the pending US acquirors). Regarding AstraZeneca, we note that Pfizer never quantified the extent to which tax benefits were important to its evaluation of the company and thus - with other strategic attractions (oncology pipeline, EM expansion etc) - it is unclear to us whether, or to what extent, the overnight news materially diminishes the chance of Pfizer renewing its interest post 26 November."

Green light in Europe for AZN ovarian cancer drug

Also: News

,Results and news

Feb 5:

Berenberg: Hold - TP: 4800p
Jefferies: Buy - TP: 5600p,
Liberum Capital: Buy - TP: 5800p
Shore Capital: Buy

Feb 6:
Panmure Gordon: Buy - TP: 5000p
Beaufort Securities: Hold - TP: N/A
Deutsche Bank: Hold - TP: 4800p

Questor/Telegraph says Hold/Solid long term investment

Feb 9: Citigroup: Buy - TP: 5400p

Questor share tip: AstraZeneca remains solid long term investment

Feb 10: Barclays: Underweight - TP: 4400p

Feb 13: Credit Suisse -Neutral - TP: 4670p

AZN Airways

Astra Zeneca's patent on asthma drug invalidated by US court

Astra considering appeal

Feb 20: Jefferies: Buy - TP: 5600p

Feb 24:

Kepler Cheuvreux: Reduce - TP: 3700p
Credit Suisse: Neutral - TP: 4670p

Feb 25:
Citigroup: Buy - TP: 5400p
JP Morgan: Neutral - TP: 4300p

Mar 10:
Jefferies:: Buy - TP: 5600p
JP Morgan: Neutral - TP: 4300p

Mar 11; Citigroup: Buy - TP: 5400p